Morgan Stanley
NXTC icon

Morgan Stanley’s NextCure NXTC Stock Holding History

Morgan Stanley’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$705 Hold
66
– – ﹤0.01% 7535
2025
Q4 		$937 Buy
+66
New +$684 ﹤0.01% 7384
2025
Q1 		– Hold
0
– -$1 – 8182
2024
Q4 		– Hold
0
– – – 7960
2024
Q3 		– Hold
0
– – – 7920
2024
Q2 		– Sell
-33,522
Closed -$652K – 7832
2024
Q1 		$897K Buy
33,522
+20,051
+149% +$345K ﹤0.01% 5019
2023
Q4 		$184K Buy
+13,471
New +$195K ﹤0.01% 5974
2023
Q3 		– Sell
-25
Closed -$477 – 7603
2023
Q2 		$542 Sell
25
-9,837
-100% -$194K ﹤0.01% 7372
2023
Q1 		$175K Buy
9,862
+7,332
+290% +$141K ﹤0.01% 5763
2022
Q4 		$42.8K Sell
2,530
-1,004
-28% -$23.1K ﹤0.01% 6359
2022
Q3 		$117K Sell
3,534
-246
-7% -$12.5K ﹤0.01% 6000
2022
Q2 		$213K Sell
3,780
-2,090
-36% -$109K ﹤0.01% 5865
2022
Q1 		$342K Sell
5,870
-205
-3% -$12.8K ﹤0.01% 5607
2021
Q4 		$438K Sell
6,075
-6,883
-53% -$576K ﹤0.01% 5621
2021
Q3 		$1.05M Sell
12,958
-35,079
-73% -$3.08M ﹤0.01% 5013
2021
Q2 		$4.63M Sell
48,037
-33,483
-41% -$3.43M ﹤0.01% 3861
2021
Q1 		$9.79M Sell
81,520
-100,282
-55% -$14.5M ﹤0.01% 2680
2020
Q4 		$23.8M Buy
181,802
+92,769
+104% +$12M ﹤0.01% 1643
2020
Q3 		$9.4M Buy
89,033
+61,403
+222% +$7.55M ﹤0.01% 2084
2020
Q2 		$7.11M Buy
27,630
+27,005
+4,321% +$10.3M ﹤0.01% 2304
2020
Q1 		$278K Sell
625
-1,505
-71% -$804K ﹤0.01% 4721
2019
Q4 		$1.44M Buy
2,130
+1,227
+136% +$616K ﹤0.01% 4278
2019
Q3 		$334K Buy
903
+339
+60% +$110K ﹤0.01% 4875
2019
Q2 		$101K Buy
+564
New +$117K ﹤0.01% 5316

Other funds holding NXTC

SCM
Squadron Capital Management Westmont, Illinois $273M AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

Morgan Stanley's NXTC Position: Q1 2026 in Review

Morgan Stanley held its NextCure (NXTC) position steady in Q1 2026 at 66 shares worth $705. The position accounts for ﹤0.01% of the portfolio, ranked #7535.

Morgan Stanley first reported a position in NXTC in Q2 2019 and has held it in 21 quarters since. The position peaked at $23.8M in Q4 2020. 26 funds tracked by Wall St. Rank hold NXTC as of Q1 2026.

  • Morgan Stanley held 66 shares of NextCure worth $705 as of Q1 2026.
  • Morgan Stanley left its NextCure share count unchanged in Q1 2026.
  • NextCure made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7535 holding.
  • Morgan Stanley first reported a position in NextCure in Q2 2019 and has held it in 21 quarters since.
  • Morgan Stanley's NextCure position peaked at $23.8M in Q4 2020.
  • 26 funds tracked by Wall St. Rank held NextCure as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.